Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Magrolimab - Forty Seven

Next Previous
Drug Profile

Magrolimab - Forty Seven

Alternative Names: 5F9; GS-4721; Hu5F9 G4; Magrolimab - Forty-Seven/Stanford-University; ONO 7913

Latest Information Update: 26 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Forty Seven; Gilead Sciences; M. D. Anderson Cancer Center; Merck KGaA; Merck Sharp & Dohme; National Cancer Institute (USA); Ono Pharmaceutical; Roche; Stanford University; University of California at San Francisco
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours; Triple negative breast cancer
  • Phase I Brain cancer; Cutaneous B-cell lymphoma; Lymphoma; Neuroblastoma; Osteosarcoma; Pancreatic cancer
  • No development reported Ovarian cancer

Most Recent Events

  • 16 Apr 2024 Gilead Sciences terminates phase III ENHANCE-3 trial in Acute myeloid leukaemia due to futility in Austria, Belgium, Canada, Czech Republic, Hungary, Israel, Taiwan, Switzerland, Poland, Norway, Netherlands, South Korea, Australia, France, Germany, Hong Kong, Italy, United Kingdom (NCT05079230)
  • 01 Mar 2024 Gilead Sciences completes a phase II trial in Acute myeloid leukaemia (Combination therapy, Newly-diagnosed, Second line therapy or greater) in USA, Australia, United Kingdom (IV) (NCT04778410)
  • 01 Mar 2024 Gilead Sciences suspends a phase II trial for Head and neck cancer (Combination therapy, Late-stage disease, Locally recurrent, Metastatic disease, Second-line therapy or greater) in the USA (IV, Infusion), as per PI request (NCT06046482)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top